Adimab, Inc. Receives Series C Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea916dda-1b46-4da8-97cb-a8ce2fed1381&Preview=1 -
Date
11/20/2008 -
Company Name
Adimab, Inc. -
Mailing Address
16 Cavendish Court Lebanon, NH 03766 -
Company Description
Adimab–which stands for Antibody Discovery Maturation Biomanufacturing–is developing a platform that’s deliberately engineered to minimize and potentially eliminate third party royalties, offering a one-stop-service-shop to a select few Big Pharma partners. -
Website
http://www.adimab.com -
Transaction Type
Venture Equity -
Transaction Amount
Undisclosed -
Transaction Round
Series C -
Proceeds Purposes
Proceeds from the financing will be used to increase the capacity for conducting multiple parallel discovery programs as well as automating several aspects of our antibody discovery process. -
M&A Terms
-
Venture Investor
OrbiMed -
Venture Investor
Borealis Ventures -
Venture Investor
SV Life Sciences -
Venture Investor
Polaris Venture Partners
